Literature DB >> 11529855

Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements.

T Shimamoto1, T Iguchi, K Ando, T Katagiri, T Tauchi, Y Ito, M Yaguchi, K Miyazawa, Y Kimura, M Masuda, H Mizoguchi, K Ohyashiki.   

Abstract

Myelodysplastic syndrome (MDS) with erythroid hypoplasia, a rare form of MDS, has not yet been clearly defined. We report four patients with MDS with erythroid hypoplasia who received immunosuppressive therapy. All were elderly, had severe transfusion-dependent anaemia, morphological evidence of myelodysplasia and a low percentage (3.2-13.6%) of erythroid precursors. Administration of cyclosporin A (CsA) improved their anaemia; all transfusion-dependent patients achieved transfusion-independence. An inverted CD4/8 ratio was seen in three patients who also demonstrated T-cell receptor (TCR)-beta and -gamma gene rearrangements by Southern blotting and clonality by polymerase chain reaction. Treatment with CsA can be an attractive alternative treatment for patients with MDS with erythroid hypoplasia, which may be associated with a clonal abnormality in T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529855     DOI: 10.1046/j.1365-2141.2001.02925.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.

Authors:  Tapan M Kadia; Gautam Borthakur; Guillermo Garcia-Manero; Stefan Faderl; Elias Jabbour; Zeev Estrov; Sergerrne York; Xuelin Huang; Sherry Pierce; Mark Brandt; Charles Koller; Hagop M Kantarjian; Farhad Ravandi
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

2.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

Review 3.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

4.  Spontaneous remission of Epstein-Barr virus-negative non-Hodgkin's lymphoma after withdrawal of cyclosporine in a patient with refractory anemia.

Authors:  Masao Ogata; Hiroshi Kikuchi; Keiji Ono; Eiichi Ohtsuka; Ayako Gamachi; Kenji Kashima; Masaru Nasu
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 5.  Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review.

Authors:  Masao Ogata; Eiichi Ohtsuka; Tomoyuki Imamura; Junji Ikewaki; Yuko Ogata; Kazuhiro Kohno; Toshiyuki Nakayama; Keiji Ono; Yoshio Saburi; Hiroshi Kikuchi; Masaru Nasu
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

6.  Immune dysregulation in myelodysplastic syndrome.

Authors:  Chiharu Sugimori; Alan F List; Pearlie K Epling-Burnette
Journal:  Hematol Rep       Date:  2010-01-26

Review 7.  Autoimmune Complications in Hematologic Neoplasms.

Authors:  Wilma Barcellini; Juri Alessandro Giannotta; Bruno Fattizzo
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.